-
Something wrong with this record ?
Naphyrone (naphthylpyrovalerone): Pharmacokinetics, behavioural effects and thermoregulation in Wistar rats
N. Pinterova-Leca, RR. Horsley, H. Danda, M. Žídková, E. Lhotková, K. Šíchová, K. Štefková, M. Balíková, M. Kuchař, T. Páleníček
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32378298
DOI
10.1111/adb.12906
Knihovny.cz E-resources
- MeSH
- Rats MeSH
- Pentanones pharmacokinetics pharmacology MeSH
- Rats, Wistar MeSH
- Pyrrolidines pharmacokinetics pharmacology MeSH
- Central Nervous System Stimulants pharmacokinetics pharmacology MeSH
- Body Temperature drug effects MeSH
- Body Temperature Regulation drug effects MeSH
- Illicit Drugs pharmacokinetics pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Naphthylpyrovalerone (naphyrone) is a pyrovalerone cathinone that potently inhibits monoamine transporters and provides stimulatory-entactogenic effects. Little is known about the safety of naphyrone or its effects in vivo, and more research is needed to acquire knowledge about its fundamental effects on physiology and behaviour. Our objective was to investigate naphyrone's pharmacokinetics, acute toxicity, hyperthermic potential and stimulatory and psychotomimetic properties in vivo in male Wistar rats. Pharmacokinetics after 1 mg/kg subcutaneous (sc.) naphyrone were measured over 6 h in serum, the brain, liver and lungs. Rectal temperature (degree Celsius) was measured over 10 h in group-versus individually housed rats after 20 mg/kg sc. In the behavioural experiments, 5, 10 or 20 mg/kg of naphyrone was administered 15 or 60 min prior to testing. Stimulation was assessed in the open field, and sensorimotor processing in a prepulse inhibition (PPI) task. Peak concentrations of naphyrone in serum and tissue were reached at 30 min, with a long-lasting elevation in the brain/serum ratio, consistent with observations of lasting hyperlocomotion in the open field and modest increases in body temperature. Administration of 20 mg/kg transiently enhanced PPI. Naphyrone crosses the blood-brain barrier rapidly and is eliminated slowly, and its long-lasting effects correspond to its pharmacokinetics. No specific signs of acute toxicity were observed; therefore, clinical care and harm-reduction guidance should be in line with that available for other stimulants and cathinones.
3rd Faculty of Medicine Charles University Prague Prague Czech Republic
Department of Experimental Neurobiology National Institute of Mental Health Klecany Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012509
- 003
- CZ-PrNML
- 005
- 20231213104856.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/adb.12906 $2 doi
- 035 __
- $a (PubMed)32378298
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pinterova-Leca, Nikola $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000162424413 $7 xx0258135
- 245 10
- $a Naphyrone (naphthylpyrovalerone): Pharmacokinetics, behavioural effects and thermoregulation in Wistar rats / $c N. Pinterova-Leca, RR. Horsley, H. Danda, M. Žídková, E. Lhotková, K. Šíchová, K. Štefková, M. Balíková, M. Kuchař, T. Páleníček
- 520 9_
- $a Naphthylpyrovalerone (naphyrone) is a pyrovalerone cathinone that potently inhibits monoamine transporters and provides stimulatory-entactogenic effects. Little is known about the safety of naphyrone or its effects in vivo, and more research is needed to acquire knowledge about its fundamental effects on physiology and behaviour. Our objective was to investigate naphyrone's pharmacokinetics, acute toxicity, hyperthermic potential and stimulatory and psychotomimetic properties in vivo in male Wistar rats. Pharmacokinetics after 1 mg/kg subcutaneous (sc.) naphyrone were measured over 6 h in serum, the brain, liver and lungs. Rectal temperature (degree Celsius) was measured over 10 h in group-versus individually housed rats after 20 mg/kg sc. In the behavioural experiments, 5, 10 or 20 mg/kg of naphyrone was administered 15 or 60 min prior to testing. Stimulation was assessed in the open field, and sensorimotor processing in a prepulse inhibition (PPI) task. Peak concentrations of naphyrone in serum and tissue were reached at 30 min, with a long-lasting elevation in the brain/serum ratio, consistent with observations of lasting hyperlocomotion in the open field and modest increases in body temperature. Administration of 20 mg/kg transiently enhanced PPI. Naphyrone crosses the blood-brain barrier rapidly and is eliminated slowly, and its long-lasting effects correspond to its pharmacokinetics. No specific signs of acute toxicity were observed; therefore, clinical care and harm-reduction guidance should be in line with that available for other stimulants and cathinones.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a tělesná teplota $x účinky léků $7 D001831
- 650 _2
- $a termoregulace $x účinky léků $7 D001833
- 650 _2
- $a stimulanty centrálního nervového systému $x farmakokinetika $x farmakologie $7 D000697
- 650 _2
- $a zakázané drogy $x farmakokinetika $x farmakologie $7 D013287
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pentanony $x farmakokinetika $x farmakologie $7 D010422
- 650 _2
- $a pyrrolidiny $x farmakokinetika $x farmakologie $7 D011759
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horsley, Rachel R $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000325362465
- 700 1_
- $a Danda, Hynek, $d 1988- $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0311507
- 700 1_
- $a Žídková, Monika $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/000000017891277X $7 xx0207762
- 700 1_
- $a Lhotková, Eva $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Šíchová, Klára $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Štefková, Kristýna $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Balíková, Marie $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000163341177 $7 jn99240000049
- 700 1_
- $a Kuchař, Martin $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $u Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology in Prague, Prague, Czech Republic
- 700 1_
- $a Páleníček, Tomáš $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000231099539
- 773 0_
- $w MED00006247 $t Addiction biology $x 1369-1600 $g Roč. 26, č. 2 (2021), s. e12906
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32378298 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20231213104852 $b ABA008
- 999 __
- $a ok $b bmc $g 1789914 $s 1163710
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 26 $c 2 $d e12906 $e 20200507 $i 1369-1600 $m Addiction biology $n Addict Biol $x MED00006247
- LZP __
- $a Pubmed-20220425